Genaera
New activities and developments reported by Genaera
Published in Fitness and Wellness Business Week, April 25th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Genaera.
Report 1: Genaera Corporation (GENR) announced that following a comprehensive review of its development portfolio and external market conditions, the board of directors and management have determined that it is in the best interest of the company to terminate the Evizon (squalamine lactate) clinical development program in wet age-related macular degeneration (AMD) and focus company resources on the development of trodusquemine (MSI-1436) for the treatment of obesity.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness and Wellness Business Week
More Articles from Fitness and Wellness Business Week
- Acidosis Therapy
Study data from North Shore University update understanding of acidosis therapy - Adipose Tissue
Findings in adipose tissue reported from Chiba University - Alcoholism
Scientists at University of Sao Paulo, Department of Gastroenterology report research in alcoholism - Alcoholism Histology
Data from Kurume University advance knowledge in alcoholism histology - Altarum Institute
Our Health, Our Workforce: Can Michigan Make Employee Health a Competitive Advantage? - Asthma
Genaera Corporation Completes Strategic Review and Announces Plan to Focus Resources on Obesity and Asthma Programs - More from this issue of Fitness and Wellness Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
